• Neuren receives first sales milestone payment of US$50 million from DAYBUE (trofinetide) commercialization in North America
• DAYBUE net sales in the US exceeded US$250 million in 2024
• Neuren has an exclusive worldwide license with Acadia Pharmaceuticals for the development and commercialization of trofinetide

Neuren Pharmaceuticals has announced that it has received a cash payment of US$50 million, which is the first sales milestone payment due for the commercialization of DAYBUE (trofinetide) in North America. This milestone payment was triggered after Neuren's partner Acadia Pharmaceuticals reported 2024 net sales of DAYBUE in the United States of US$348.4 million, exceeding the initial threshold of US$250 million. Neuren has an exclusive worldwide license agreement with Acadia Pharmaceuticals for the development and commercialization of trofinetide. Under the terms of this agreement, Neuren is entitled to receive additional milestone payments based on increasing levels of DAYBUE net sales in North America, up to a total of US$450 million. DAYBUE is approved by the US FDA and Health Canada for the treatment of Rett syndrome, a rare and serious neurological disorder that emerges in early childhood. Neuren is also developing its second drug candidate, NNZ-2591, for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials for Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome.

Neuren is entitled to receive additional sales milestone payments from Acadia Pharmaceuticals based on increasing levels of DAYBUE net sales in North America, up to a total of US$450 million.